Papke, RL Buhr, JD Francis, MM Choi, KI Thinschmidt, JS Horenstein, NA 2024-01-21T05:02:37Z 2024-01-21T05:02:37Z 2021-09-01 2005-06 0026-895X https://pubs.kist.re.kr/handle/201004/136447 The therapeutic targeting of nicotinic receptors in the brain will benefit from the identification of drugs that may be selective for their ability to activate or inhibit a limited range of nicotine acetylcholine receptor subtypes. In the present study, we describe the effects of 2,2,6,6-tetramethylpiperidin-4-yl heptanoate ( TMPH), a novel compound that is a potent inhibitor of neuronal nicotinic receptors. Evaluation of nicotinic acetylcholine receptor (nAChR) subunits expressed in Xenopus laevis oocytes indicated that TMPH can produce a potent and long-lasting inhibition of neuronal nAChR formed by the pairwise combination of the most abundant neuronal alpha (i.e., alpha 3 and alpha 4) and beta subunits (beta 2 and beta 4), with relatively little effect, because of rapid reversibility of inhibition, on muscle-type (alpha 1 beta 1 gamma delta) or alpha 7 receptors. However, the inhibition of neuronal beta subunit-containing receptors was also decreased if any of the nonessential subunits alpha 5, alpha 6, or beta 3 were coexpressed. This decrease in inhibition is shown to be associated with a single amino acid present in the second transmembrane domain of these subunits. Our data indicate great potential utility for TMPH to help relate the diverse central nervous system effects to specific nAChR subtypes. English AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS ACETYLCHOLINE-RECEPTORS MECAMYLAMINE SUBTYPES PHARMACOLOGY RESPONSES The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4-yl heptanoate Article 10.1124/mol.105.011676 1 MOLECULAR PHARMACOLOGY, v.67, no.6, pp.1977 - 1990 MOLECULAR PHARMACOLOGY 67 6 1977 1990 scie scopus 000229141200018 2-s2.0-21744435770 Pharmacology & Pharmacy Pharmacology & Pharmacy Article ACETYLCHOLINE-RECEPTORS MECAMYLAMINE SUBTYPES PHARMACOLOGY RESPONSES nicotinic receptors inhibition